# US 2026/0083752 A1 · Pharmaceutical methods, compositions and combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083752 A1
- Document ID: US20260083752A1
- Status: Published application
- Kind: A1
- Application number: 19/334,371
- Filed: 2025-09-19
- Published: 2026-03-26
- Earliest claimed: 2024-09-20
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Darko Bosnakovski; Erdong Wei
- Web page: https://patentgrep.com/patent/US20260083752A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods for treating cancer in an animal in need thereof, comprising administering to the animal a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions and pharmaceutical combinations, comprising a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method for treating cancer in an animal in need thereof, comprising administering (e.g., co-administering) to the animal a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof.

### Claim 2

A pharmaceutical composition or pharmaceutical combination, comprising a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator is a p300/CBP (p300 and/or CBP) inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator is a p300/CBP (p300 and/or CBP) degrader.

### Claim 5 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator is a p300/CBP (p300 and/or CBP) histone acetyltransferase (HAT) inhibitor or bromodomain inhibitor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof is B029-2, XP-524, A-485, CCS1477, NE02734, B026, FT-7051 or a compound (e.g., p300/CBP inhibitor) or a pharmaceutically acceptable salt thereof as described in WO 2016/044770.

### Claim 7 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator (e.g., inhibitor) is a compound of formula (I) (iP300w):
or a pharmaceutically acceptable salt thereof to the animal.

### Claim 8 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof is a p300/CBP (p300 and/or CBP) degrader.

### Claim 9 (depends on 1)

The method of claim 1, wherein the p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof is a PROTAC.

### Claim 10 (depends on 9)

The method of claim 9, wherein the PROTAC is BT-02C, dCBP-1, or JQAD1.

### Claim 11 (depends on 1)

The method of claim 1, wherein the senotherapeutic or a pharmaceutically acceptable salt thereof is Dasatinib, Fisetin, Navitoclax, or Quercetin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the senotherapeutic is a tyrosine kinase inhibitor (TKI) or a pharmaceutically acceptable salt thereof, selected from the group consisting of Dasatinib, Imatinib, Nilotinib, Bosutinib, Ponatinib, or Asciminib, Sunitinib, Sorafenib, Axitinib, Lenvatinib, Gefitinib, Erlotinib, Vandetanib, Cabozantinib, Pazopanib, Crizotinib, Ceritinib, Brigatinib, Larotrectinib, Entrectinib, Regorafenib, Osimertinib, Alectinib, Trametinib, Neratinib, and Tucatinib.

### Claim 13 (depends on 1)

The method of claim 1, wherein the senotherapeutic is a PI3K (phosphoinositide 3-kinase) inhibitor or a pharmaceutically acceptable salt thereof, selected from the group consisting of Idelalisib, Alpelisib, Copanlisib, Duvelisib, Buparlisib, Pictilisib, Apitolisib, Dactolisib, Taselisib, Omipalisib, Voxtalisib.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is a cancer driven by an oncogene that is dependent on p300/CBP (p300 and/or CBP) activity (e.g., the method to reduce the proliferation of oncogene-driven cancer cells).

### Claim 15 (depends on 14)

The method of claim 14, wherein the oncogene is EWSR1::FLI1, EWSR1::ERG, AML::ETO, ATXN1::DUX4, CIC::DUX4, CIC::FOXO4, CIC::NUTM1, CIC::LEUTX, MYB::NFIB, RUNX1::ETO, PAX3::FOXO1, PAX3::FOXO4, PAX3::INO80D, PAX3::AFX, PAX3::NCOA1, PAX3::NCOA2, BCOR::CCNB3, BCOR::MAML3, BCOR::ITD, PAX7::FOXO1, ASPSCR1::TFE3, EWSR1::CREB1, EWSR1::ATF1, PAX3::MAML3, MECT1::MAML2, BRD4::NUTM1, BRD3::NUTM1, NSD3::NUTM1, YWHAE::NUTM2, EWSR1::WT1, EP300::BCOR, FUS::ERG, FUS::CREB3L1, FUS::CREB3L2a, EWSR1::CREB3L1, EWSR1::CREB3L2, FUS::CREB3L2, FUS::DDIT3a, NAB2::STAT6, VGLL2::CITED2, SS18::SSX1, SS18::SSX2, SS18::SSX4, SS18L1::SSX1, BCOR::MAML3, NUTM2A::CIC, YWHAE::NUTM2B, EWSR1::SP3, PAX8::PPARG, RUNX1::ET, TMPRSS2::ERG, TMPRSS2::ETV1, or TMPRSS2::ETV4.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is a pediatric sarcoma, CIC-rearranged sarcoma, Ewing sarcoma, or CIC-DUX4 sarcoma.

### Claim 17

A pharmaceutical composition or pharmaceutical combination comprising a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof for medical treatment.

### Claim 18

The use of a pharmaceutical composition or pharmaceutical combination comprising a p300/CBP (p300 and/or CBP) modulator or a pharmaceutically acceptable salt thereof and a senotherapeutic (e.g., a senolytic or senomorphic) or a pharmaceutically acceptable salt thereof for the treatment of cancer.

### Claim 19

(canceled)